<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016020726407N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-09-15</date_registration>
      <primary_sponsor>Vice chancellor for research,Traditional Medicine College of Shahid Beheshti University of Medical S</primary_sponsor>
      <public_title>Effect of flaxseed oil on clinical sign of Knee Arthrosis</public_title>
      <acronym></acronym>
      <scientific_title>Efficacy of "Linum usitatissimum" Seed topical oil, on Clinical Sign of Knee Osteoarthritis Compared with Placebo, A Double Blind Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-07-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/21900</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2-3</phase>
      <hc_freetext>knee osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Linum usitatissimum seed topical oil  20 drops every 8 hours without massage for 6 weeks, in case of pain, up to 3 tablets of diclofenac 50 mg is permitted. Intervention 2: Control group: placebo; paraffin oil with the same method and order of  intervention groups and  for 6 weeks, in case of pain, up to 3 tablets of diclofenac 50 mg is permitted.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nematollah Masoudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.8 Shams Alley, Opposite Tavanir St, Vali Asr St, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8877 2521</telephone>
        <email>nmasoudi@sbmu.ac.ir; salman.farsy@gmail.com</email>
        <affiliation>College of Traditional Medicine, Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahmood Khodadoost</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.8 Shams Alley, Opposite Tavanir St, Vali Asr St, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8877 2521</telephone>
        <email>mkhodadoost@LMO.ir;  mkhodadoost2010@yahoo.com</email>
        <affiliation>Traditional Medicine College of Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Patient between 40 to 70 yaers age with BMI less than 35 that fill clinical and radiologic criteria of ACR  and have Kellgren-Lawrence Grading Scale III / II / I, with VAS over than 4 cm; Clinical and radiological criteria of ACR include: knee pain, osteophyte in radiography, plus at least 1 of 3 below criteria: age more than 50 years old; morning stiffness less than 30 minutes; crepitation of knee. Exclusion criteria:  Acute arthritis, osteoarthritis due to rheumatologic disease such as RA and gout, infective arthritis, metabolic arthritis, traumatic, uncontrolled diabetes, known case of cardiac or hepatic disease, cancer; History of knee replacement surgery; Fibromyalgia, radiculopathy and neuropathy; Those who are unable to tolerate  and complete the study or treatment and follow-up; As well as those who use more than 3 tablets Diclofenac 50mg daily or need other oral or injection form of pain control, are excluded; At the same time, patients with Glucosamine, Chondroitin sulfate, and muscle relaxants use; sensitivity to medicinal plants; History of receiving oral or topical steroids during the 14 days prior to the study; Corticosteroids injection in the period of 30 days before study; pregnancy, hepatorenal active disease, gastritis, addiction to alcohol and narcotic drugs, skin disease of knee, those receiving antidepressant for chronic pain, Also, people who have mild and intermittent pain that only require non-pharmacological recommendations; New forms of therapies such as hydrotherapy, physiotherapy, start to interfere with the study.</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Gonarthrosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Linum usitatissimum seed topical oil  20 drops every 8 hours without massage for 6 weeks, in case of pain, up to 3 tablets of diclofenac 50 mg is permitted</i_keyword>
      <i_keyword>Control group: placebo; paraffin oil with the same method and order of  intervention groups and  for 6 weeks, in case of pain, up to 3 tablets of diclofenac 50 mg is permitted</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: At the beginning of intervention and  6 weeks  after the beginning of intervention. Method of measurement: KOOS Pain and VAS.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Knee discomfort. Timepoint: At the beginning of intervention and  6 weeks after the beginning of intervention. Method of measurement: KOOS Scoring.</sec_outcome>
      <sec_outcome>Stiffness. Timepoint: At the beginning of intervention and 6 weeks after  the beginning of intervention. Method of measurement: KOOS Scoring.</sec_outcome>
      <sec_outcome>Activities and daily living. Timepoint: At the beginning of intervention and  6 weeks after the beginning of intervention. Method of measurement: KOOS Scoring.</sec_outcome>
      <sec_outcome>Sport and recreation function. Timepoint: At the beginning of intervention and   6 weeks after the beginning of intervention. Method of measurement: KOOS Scoring.</sec_outcome>
      <sec_outcome>Quality of life. Timepoint: At the beginning of intervention and 6 weeks  after  the beginning of intervention. Method of measurement: KOOS Scoring and SF26 WHO.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research,Traditional Medicine College of Shahid Beheshti University of Medical S</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-07-03</approval_date>
        <contact_name>Ethics Committee in Biomedical Research, Shahid Beheshti University of Medical Sciences (IR.SBMU.REC</contact_name>
        <contact_address>Office of Research Management, Shahid Beheshti University of Medical Sciences, side of Taleghani Hospital, Evin, Shahid Chamran Highway, Tehran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
